Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Skin & Hair
Research dose range
Standard research range
1 - 2 mg
The primary working range for consistent follicle support.
Research focus
Hair follicle stimulation
Observed window
4-8 week active cycles
Administration
Once daily
Primary pathway
Dermal papilla cells (DPC), VEGF, TGF-β1
All dosing figures are extrapolated from GHK-Cu community protocols (a structurally related compound differing by one amino acid) — no AHK-Cu-specific injectable data exists, published or community-sourced. No human clinical trial supports injectable administration of either compound. For research use only.
MANFAAT PROTOKOL
◆
Directly stimulates dermal papilla cells — the master regulators at the base of each hair follicle — while protecting them from programmed cell death.
◆
Increases VEGF to improve blood supply to follicles, while suppressing TGF-β1, the signal that pushes follicles prematurely out of the growth phase.
◆
One amino acid swap from GHK-Cu redirects the entire effect — trading broad tissue repair for a mechanism concentrated specifically on the follicle microenvironment.
SAINS
AHK-Cu is a copper tripeptide — alanine, histidine, lysine, bound to copper — differing from its sister peptide GHK-Cu by a single amino acid substitution. That one change redirects the biology: instead of GHK-Cu's broad tissue-remodeling activity, AHK-Cu concentrates specifically on dermal papilla cells, the fibroblasts controlling each follicle's growth cycle.
The mechanism data comes from Seoul National University's ex vivo and in vitro research, not a human injectable trial — AHK-Cu increased VEGF, suppressed TGF-β1, and cut two separate cell-death markers by 43% and 78% at very low concentrations. Systemic delivery via injection follows the pattern set by its sister compound GHK-Cu, which research communities have used subcutaneously for years to extend copper-peptide signaling beyond the skin's surface — though neither compound has a published human trial confirming an optimal injectable protocol.
YANG DIHARAPKAN
Effects build on the hair growth cycle's own timeline, not overnight — anagen, the active growth phase, runs 2-7 years regardless of intervention. Community-cited injectable cycles for this compound class run 4-8 weeks active, followed by a break before resuming.
CATATAN PROTOKOL
Available in 50mg. For research use only. Full documentation included with every order.
FAQ
A single amino acid substitution — alanine in place of glycine — shifts AHK-Cu's mechanism away from GHK-Cu's broad tissue-repair activity and concentrates it specifically on dermal papilla cells at the hair follicle.
No AHK-Cu-specific injectable dosing data exists — published or community-sourced. The figures here are extrapolated from GHK-Cu's community SC protocol, the closest structural analog available.
